Lu Gan

Company: X4 Pharmaceuticals

Job title: Senior Director - Medical

Seminars:

SRK-181, A Latent TGF-β Inhibitor: Safety & Efficacy Results From the Dose Escalation Portion of a Phase I Trial (DRAGON Trial) in Patients with Advanced Solid Tumors 4:00 pm

Exploring the SRK-181 mechanism of action and study design Navigating dose escalation and safety data to determine how high the dose and what the safety profile of the therapeutic looks likeRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.